Bayer Ponders Road Less Traveled And Trip Savings In Pandemic
Travel Costs Halved From €600-700m Per Year Before COVID
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
You may also be interested in...
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.
The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.
Sanofi is the latest drugmaker to announce a major initiative aimed at improving access to medicines in poorer countries, the type of move that should continue to lift the reputation of big pharma above the likes of big oil and big tobacco.